ES71
TEAS SECTION 71 RECEIVED
05/18/2026
Back to search
Official data from USPTO
KYOWA KIRIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
05/19/2026
Trademark type
Combined
Nice classes
5, 40, 42, 44
Filing date
01/25/2019
Registration date
05/19/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/19/2020
Last transaction
05/19/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
JP
Examiner
CHANG, ELIZABETH YI HSUAN
Law office
O30
Current location
POST REGISTRATION
Mark description
The mark consists of the stylized wording "KYOWA KIRIN" wherein the initial letter "K" is superimposed over two overlapping irregular ovals.
Holders and representatives
Holders
KIRIN HOLDINGS KABUSHIKI KAISHA (also trading as Kirin Holdings Company, Limited)
KIRIN KABUSHIKI KAISHA (also trading as KIRIN Company, Limited)
Representatives
Charles T. J. Weigell Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of cancer or malignant tumorspainhematological disordersrenal diseaseendocrine diseasesimmunity disordersneurologicalpsychiatric and other central nervous system disorders; pharmaceutical preparations for supportive care in the treatment of cancer or malignant tumors; diagnostic preparations for medical purposes; chemical reagents for medical or veterinary purposes; cells for medical purposes; bacteriological culture mediums for medical and veterinary purposes; cell culture mediums for medical and veterinary purposes; reagent paper for medical purposes; gauze for dressings; empty capsules for pharmaceuticals; antiseptic absorbent cotton; adhesive plasters for medical purposes; bandages for dressings; lacteal flour for babies; dietary supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies adapted for medical purposes; food for babies; dietary supplements for animals
Class 40
Custom manufacture of pharmaceuticals; extractionproduction and synthesis of pharmaceuticals for others; custom manufacture of industrial chemicals; custom manufacture of medical apparatus and medical instruments; manufacture of antibody-producing cells for others
Class 42
Pharmaceutical research; research of chemicals; analysis of chemicals; testinginspection or research of pharmaceuticals; testinginspection or research of chemicals; testinginspection or research of cosmetics; testinginspection or research of foodstuff; providing technical advice relating to chemical research; providing technical advice relating to pharmaceutical development; providing technical advice relating to chemical development; rental of laboratory apparatus; rental of laboratory instruments
Class 44
Providing medical information; medical examinations; preparation and dispensing of medication; dietary and nutritional guidance; veterinary services; rental of medical apparatus; rental of medical instruments
Publications
History of USPTO decisions and trademark events.
34 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/23/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
05/19/2025
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
10/29/2021
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
10/28/2021
PLGL
ASSIGNED TO PARALEGAL
10/28/2021
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
10/23/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/19/2020
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
09/23/2020
XXCR
GENERIC MADRID TRANSACTION CREATED
09/23/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/19/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
05/19/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/03/2020
PUBO
PUBLISHED FOR OPPOSITION
03/03/2020
GPNX
NOTIFICATION PROCESSED BY IB
02/28/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/12/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/12/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/12/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/30/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/29/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/29/2020
ALIE
ASSIGNED TO LIE
01/29/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/22/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/01/2019
CHLD
CHANGE OF OWNER RECEIVED FROM IB
10/10/2019
RFNT
REFUSAL PROCESSED BY IB
08/09/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/23/2019
RFRR
REFUSAL PROCESSED BY MPU
07/23/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/02/2019
MAFR
APPLICATION FILING RECEIPT MAILED
07/02/2019
CNRT
NON-FINAL ACTION WRITTEN
07/01/2019
DOCK
ASSIGNED TO EXAMINER
06/26/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/26/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/20/2019
Continuous trademark protection
Get notified about every new filing that threatens KYOWA KIRIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.